Frazier Financial Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.17M Sell
16,576
-1,459
-8% -$314K 2.11% 10
2026
Q1
$3.92M Buy
18,035
+351
+2% +$77.9K 2.17% 11
2025
Q4
$4.04M Sell
17,684
-224
-1% -$51K 2.39% 9
2025
Q3
$4.15M Hold
17,908
2.55% 9
2025
Q2
$3.32M Sell
17,908
-77
-0.4% -$14.3K 2.35% 12
2025
Q1
$3.77M Sell
17,985
-400
-2% -$77.8K 2.91% 11
2024
Q4
$3.24M Buy
18,385
+1,250
+7% +$230K 2.57% 11
2024
Q3
$3.38M Buy
17,135
+30
+0.2% +$5.6K 2.63% 9
2024
Q2
$2.93M Buy
17,105
+88
+0.5% +$14.6K 2.33% 10
2024
Q1
$3.1M Sell
17,017
-1,044
-6% -$180K 2.54% 9
2023
Q4
$2.8M Buy
+18,061
New +$2.63M 2.43% 9

Other funds holding ABBV

Frazier Financial Advisors's ABBV Position: Q2 2026 in Review

Frazier Financial Advisors reduced its AbbVie (ABBV) stake by 8.1% in Q2 2026, selling an estimated $314K and leaving 16,576 shares worth $4.17M. The position accounts for 2.11% of the portfolio, ranked #10.

Frazier Financial Advisors first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,214 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Frazier Financial Advisors held 16,576 shares of AbbVie worth $4.17M as of Q2 2026.
  • Frazier Financial Advisors sold 1,459 AbbVie shares in Q2 2026, an estimated $314K.
  • AbbVie made up 2.11% of Frazier Financial Advisors's portfolio in Q2 2026, its #10 holding.
  • Frazier Financial Advisors first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 4,214 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Frazier Financial Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.